Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: Biochim Biophys Acta. 2017 Jun 3;1863(9):2149–2157. doi: 10.1016/j.bbadis.2017.06.001

Fig. 2.

Fig. 2

Effects of different doses of anti-Tim1 treatment on CD1dhighCD5+ B cells frequency, IL-10 protein expression and mRNA level. Splenocyte B cells were separated from C57/BL6J mice and cultured 48 h with anti-Tim1 at dosages 2.5 μg/ml, 5 μg/ml, 10 μg/ml and 20 μg/ml. CD1dhighCD5+ B cells were detected using flow cytometry in control and anti-Tim1 treatment groups (A) (X-axis: CD5 PE staining; Y-axis: CD1d APC staining). The percentage (B) and quantity (C) of CD1dhighCD5+ B cells were quantified and analyzed by FlowJo software (mean ± SD, n= 4 mice per group, compared with control group, **p < 0.01). IL-10 mRNA levels in total cell lysis were determined by real-time PCR in control and anti-Tim1 treatment groups (D) (mean ± SD, n =4 mice per group, compared with control group no significant differences). Medium supernatants were collected and secreted IL-10 protein levels were measured by ELISA in control and anti-Tim1 treatment groups (E) (mean ± SD, n = 4 mice per group, compared with control group no significant differences).